Feed GILD
GI

Gilead Sciences

GILD · NASDAQ

$143.72 -1.05% (-$1.52)
1M +3.87%
Market Cap $179.8B
P/E Ratio -
Div. Yield 2.22%
ROE 16.28%

Bulios Fair Price

$146.62

2.0% upside

Trenutna cena

$143.72

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price se delnica GILD trenutno trguje blizu svoje poštene vrednosti. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
5/9
Valuation
45 /100
Fair
EV/EBITDA 318.96x
PEG 0.01x
P/S 5.90x
Growth
56 /100
Stable
EPS growth 23.04%
Book val. growth 2.12%
Rev. growth 2.57%
Profitability
50 /100
Moderate
Gross margin 79.59%
FCF margin 43.34%
Net margin 10.64%
Quality
8 /100
Poor
ROIC 6.07%
Asset turnover 0.62x
ROE 16.28%
Debt
12 /100
High
Debt/Equity 2.22x
Net debt/EBITDA 36.27x
Current ratio 1.27x
Stability
54 /100
Moderate
Beta 0.35x
Profitable years 6
Rev. volatility 3.33%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o GILD
Online

O podjetju

Gilead Sciences, Inc. (GILD) is an American biopharmaceutical company specializing in research, development, and manufacturing of pharmaceuticals in the field of infectious diseases, viral diseases, and chronic conditions, such as HIV/AIDS, hepatitis C, hepatitis B, and more. The company is renowned for its innovative treatment approaches and drugs that have a significant impact on improving the quality of life for patients worldwide. Gilead Sciences is actively engaged in research and collaborates with academic institutions and healthcare organizations to discover new therapies and medications. With successful products and a strong research background, Gilead Sciences, Inc. has the potential for further innovations and expanding its pharmaceutical portfolio. Investing in Gilead Sciences, Inc. (GILD) shares may present an interesting choice for investors who follow the pharmaceutical sector and seek a company with a track record of successful products and commitment to combating serious diseases.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Daniel O'Day

Employees

17,000

Headquarters

Foster City

Prihajajoči dogodki

15 SEP.

Ex-Dividend

Ex-dividend date

2d
29 SEP.

Dividend Payment

Datum plačila

16d
29 OKT.

Earnings

Upcoming earnings report

46d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.